Skip to main content

American Thoracic Society

Events
Search
Sign Up
Sign In

Item Added to Cart

You just added

You have item(s) in your cart

  • Proceed to Checkout

REPLACE: (Riociguat rEplacing PDE5i therapy evaluated Against Continued PDE5i therapy): A Look at Phase IV Study Data

  • Overview
  • Resources

Thank you

Thank you for joining our webinar today sponsored by Bayer. Industry Innovations Webinars are archived on the ATS YouTube channel.

Description

Managing adult PAH (WHO Group 1) patients at intermediate risk. A look at REPLACE: Phase IV Study data.

Please join us for an exciting webinar releasing data from the Phase IV REPLACE (Riociguat rEplacing PDE-5i therapy evaLuated Against Continued PDE-5i thErapy) study.

The REPLACE study was a prospective, randomized, controlled, open label, international, multicenter study evaluating the efficacy of Adempas in adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1) who are receiving a stable dose of a PDE5i and still at intermediate risk.

Adempas is indicated for the treatment of adult patients with PAH to improve exercise capacity, improve WHO Functional Class (FC), and delay clinical worsening.* Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists (ERA) or prostanoids (PCA). Studies establishing effectiveness included predominantly patients with WHO FC II–III.

* Time to clinical worsening was a combined endpoint defined as death (all-cause mortality), heart/lung transplantation, atrial septostomy, hospitalization due to persistent worsening of pulmonary hypertension, start of a new PAH-specific treatment, persistent decrease in 6MWD, and persistent worsening of WHO functional class. 

This program is sponsored by Bayer. 


By registering for this webinar, you agree your information will be shared with the sponsor.

No CME or MOC credits are available for this program.

Opinions expressed and resources shared may not have been reviewed by the ATS prior to distribution through ATS channels, or reflect official positions of the ATS, unless it is explicitly noted as a result of official ATS approval. References to specific commercial entities (companies) or products do not reflect review or endorsement by the ATS unless it is explicitly noted as a result of official ATS approval.

Contributors

  • Roxana Sulica, MD

    Pulmonologist, Critical Care physician – NYU Langone Health, NY, NY
    Director of NYU Langone Health Pulmonary Hypertension Program

  • To learn more about the serious risks associated with Adempas, please refer to the Prescribing Information (this comes from our website, www.adempasrems.com).

    http://labeling.bayerhealthcare.com/html/products/pi/Adempas_PI.pdf

April 21, 2021
Wed 6:30 PM EDT

Duration 1H 0M

This live web event has ended.

For Technical Support
support@blueskyelearn.com
+1 (858) 201-4136
Register
Log In
  • New
  • Existing

Forgot password?
  • Events
  • Search
  • Support
  • Sign Up
  • Sign In
  • Privacy Policy | Cookies Policy